Last reviewed · How we verify
BNT162b2 mRNA Covid-19 Vaccine
BNT162b2 mRNA Covid-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response without causing the disease.
BNT162b2 mRNA Covid-19 Vaccine works by instructing cells to produce a piece of the SARS-CoV-2 virus, prompting an immune response without causing the disease. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.
At a glance
| Generic name | BNT162b2 mRNA Covid-19 Vaccine |
|---|---|
| Sponsor | Ente Ospedaliero Ospedali Galliera |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
This vaccine uses a piece of the viral genome, called messenger RNA (mRNA), to instruct cells to produce a protein from the SARS-CoV-2 virus. This protein is then recognized by the immune system, which mounts a response to the perceived threat, providing immunity against future infections.
Approved indications
- Prevention of COVID-19 disease caused by SARS-CoV-2 virus
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
- Muscle pain
- Chills
- Nausea
- Diarrhea
- Fever
Key clinical trials
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population (PHASE2)
- Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
- Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda (PHASE2)
- A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNT162b2 mRNA Covid-19 Vaccine CI brief — competitive landscape report
- BNT162b2 mRNA Covid-19 Vaccine updates RSS · CI watch RSS
- Ente Ospedaliero Ospedali Galliera portfolio CI